This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
by Ahan Chakraborty
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
by Sundeep Ganoria
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
by Kanishka Das
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
REGNPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AZNPositive Net Change MRKPositive Net Change ADMAPositive Net Change EDITPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
NVSPositive Net Change BAYRYPositive Net Change FOLDPositive Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
by Zacks Equity Research
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
ALKSPositive Net Change AGIOPositive Net Change CRMDNegative Net Change FULCNegative Net Change
biotechs medical
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMAPositive Net Change EDITPositive Net Change COGTPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKPositive Net Change GILDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
by Zacks Equity Research
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
ALKSPositive Net Change CRMDNegative Net Change AVDLPositive Net Change CSTLNegative Net Change
biotechs
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
by Zacks Equity Research
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
BIAFPositive Net Change
biotechnology biotechs earnings medical
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
by Zacks Equity Research
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
ALKSPositive Net Change INSMNegative Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
by Zacks Equity Research
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
NVOPositive Net Change VNDAPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
by Zacks Equity Research
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
ALKSPositive Net Change JAZZPositive Net Change CRMDNegative Net Change ZYMEPositive Net Change
biotechs medical
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
NVOPositive Net Change ADMAPositive Net Change ARQTPositive Net Change VTYXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
GSKPositive Net Change ADMAPositive Net Change ALECPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
by Sundeep Ganoria
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
BIIBPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
by Zacks Equity Research
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
RHHBYPositive Net Change ALKSPositive Net Change SRPTPositive Net Change CRMDNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
by Zacks Equity Research
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
BMYPositive Net Change JNJPositive Net Change CYTKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
by Kanishka Das
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
REGNPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
TEVAPositive Net Change ANIPPositive Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechs medical